A Study of Viracept in HIV-Positive Women
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: May 1999
History of Changes
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
Drug : Nelfinavir mesylate
Primary Purpose: Treatment
|Official Title:||A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Ages Eligible for Study:||13 Years and older|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
Patients must have:
- HIV infection.
- CD4 T cell count <= 400 cells/mm3.
- Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
- Prior protease inhibitor therapy.
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002171
Locations Show More
|United States, Alabama|
|Univ of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, California|
|Univ of Southern California / LA County USC Med Cntr|
|Los Angeles, California, United States, 90033|
|United States, Louisiana|
|HIV Outpatient Clinics / LA State Univ Med Ctr|
|New Orleans, Louisiana, United States, 70112|
|United States, Texas|
|Houston, Texas, United States, 77009|
Sponsors and CollaboratorsAgouron Pharmaceuticals
|Responsible Party:||Agouron Pharmaceuticals|
|ClinicalTrials.gov Identifier:||NCT00002171 History of Changes|
|Other Study ID Numbers:||259D|
|AG1343 - 534|
|Study First Received:||November 2, 1999|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:Placebos
Drug Therapy, Combination
HIV Protease Inhibitors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on January 28, 2020
This information is provided by ClinicalTrials.gov.